Cancer has no borders.
Neither do we.

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

The World’s Most Innovative Companies of 2024

BeiGene’s named one of Fast Company’s the World’s Most Innovative Companies Of 2024.

Our BTK inhibitor received its fifth approval in the U.S.

The U.S. FDA granted accelerated approval of our BTK inhibitor for the treatment of relapsed or refractory follicular lymphoma.

First doses of our BTK inhibitor administered to patients with CLL in Armenia and Nepal

The first group of patients with chronic lymphocytic leukemia in Armenia and Nepal have received treatment free of charge through our collaboration with the Max Foundation.

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

BeiGene’s named one of Fast Company’s the World’s Most Innovative Companies Of 2024.

Learn More

The U.S. FDA granted accelerated approval of our BTK inhibitor for the treatment of relapsed or refractory follicular lymphoma.

Learn More

The first group of patients with chronic lymphocytic leukemia in Armenia and Nepal have received treatment free of charge through our collaboration with the Max Foundation.

Learn More

Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More

doctor_and_patient

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More

people_walking

Our Commitment to Patients

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More

elder_women

BeiGene News

March 14, 2024

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Read more

March 13, 2024

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

Read more

March 12, 2024

Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society’s Light The Night

Read more

March 7, 2024

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

Read more

March 6, 2024

BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

Read more

February 29, 2024

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Read more